New-Onset Diabetes After Renal Transplantation

New-onset diabetes after transplantation (NODAT) is a serious and frequent metabolic complication after renal transplantation. This entity is currently well defined since the publication of the International Consensus Guidelines in 2003. Here, we review the factors contributing to the risk of NODAT and the strategies related to modifiable factors, with emphasis on practical issues. Recognizing these factors may help clinicians to evaluate prospectively appropriate prevention strategies to minimize the risk of NODAT. Over the past 50 years, the concept of NODAT has evolved in terms of name and definition. Before 2003, de novo diabetes that developed after transplantation was described in various terms, most frequently “posttransplantation diabetes mellitus,” and suffered from a lack of consensus regarding its definition. The most commonly used clinical definition was the requirement of insulin for a minimum period posttransplantation (often 30 days). This definition, however, identified only the most severe cases, leaving out the majority of patients with glucose metabolism disorders. International Consensus Guidelines on NODAT were published in 2003. They recommended that the diagnosis of NODAT should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes published in 2003 (1,2). Since then, a follow-up report from the International Expert Committee further lowered the inferior limit of fasting plasma glucose (FPG) (100 mg/dL) that corresponds to impaired fasting glucose (IFG), based on epidemiologic predictive data (3). In addition, since 2009, the International Expert Committee recommended the use of a standardized A1C assay for diabetes diagnosis (A1C level ≥6.5%), a position that has been endorsed by ADA in 2010 (4). The Expert Committee stated that A1C assay cannot be used in conditions that change red cell turnover. This is the case of end-stage renal disease (ESRD) patients and newly transplanted kidney patients. For instance, the posttransplant period is frequently associated …

[1]  C. Legendre,et al.  The ORION Study: Comparison of Two Sirolimus‐Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  D. Min,et al.  Genetic and Clinical Risk Factors of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients , 2011, Transplantation.

[3]  M. Droździk,et al.  Association of transcription factor 7-like 2 (TCF7L2) gene polymorphism with posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus , 2011, Pharmacological reports : PR.

[4]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[5]  A. Geerts,et al.  Hypomagnesemia and the risk of new‐onset diabetes after liver transplantation , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  Valerie Teal,et al.  Association of Metabolic Syndrome With Development of New-Onset Diabetes After Transplantation , 2010, Transplantation.

[7]  M. Arias,et al.  Influence of interleukin-6 promoter polymorphism -174 g/c on kidney graft outcome. , 2010, Transplantation proceedings.

[8]  Ayellet V. Segrè,et al.  Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis , 2010, Nature Genetics.

[9]  A. Hartmann,et al.  Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[10]  A. Hartmann,et al.  Glucose tolerance before and after renal transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  A. Sharif,et al.  Diagnostic application of the A(1c) assay in renal disease. , 2010, Journal of the American Society of Nephrology : JASN.

[13]  L. Rostaing,et al.  A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[15]  S. Humphries,et al.  Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study , 2010, BMJ : British Medical Journal.

[16]  M. Droździk,et al.  Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus , 2010, The Pharmacogenomics Journal.

[17]  J. Cerhan,et al.  Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. , 2009, Transplantation proceedings.

[18]  D. Abramowicz,et al.  TCF7L2 polymorphism associates with new-onset diabetes after transplantation. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  M. Kim,et al.  Association of Common Type 2 Diabetes Risk Gene Variants and Posttransplantation Diabetes Mellitus in Renal Allograft Recipients in Korea , 2009, Transplantation.

[20]  W. van Biesen,et al.  Posttransplantation Hypomagnesemia and Its Relation with Immunosuppression as Predictors of New‐Onset Diabetes after Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  A. Hartmann,et al.  Fasting Plasma Glucose and Glycosylated Hemoglobin in the Screening for Diabetes Mellitus After Renal Transplantation , 2009, Transplantation.

[22]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[23]  J. Squifflet,et al.  Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. , 2009, Journal of the American Society of Nephrology : JASN.

[24]  J. Pankow,et al.  Serological evidence of infections and Type 2 diabetes: the Multiethnic Study of Atherosclerosis , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[25]  L. Hilbrands,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2008, The New England journal of medicine.

[26]  A. Webster,et al.  Sirolimus is associated with new-onset diabetes in kidney transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.

[27]  W. Winkelmayer,et al.  Pottransplantation anemia: management and rationale. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[28]  A. Pittas,et al.  Management of glycemia in patients with diabetes mellitus and CKD. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  D. Abramowicz,et al.  Conversion from tacrolimus to cyclosporine A for new‐onset diabetes after transplantation: a single‐centre experience in renal transplanted patients and review of the literature , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[30]  Peter Almgren,et al.  Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. , 2007, The Journal of clinical investigation.

[31]  S. Chadban,et al.  Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  M. Schnitzler,et al.  Diabetic Complications Associated With New-Onset Diabetes Mellitus in Renal Transplant Recipients , 2007, Transplantation.

[33]  T. Shah,et al.  Risk Factors for Development of New-Onset Diabetes Mellitus After Kidney Transplantation , 2006, Transplantation.

[34]  J. Neilson,et al.  Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function , 2006, Nature.

[35]  M. Deschamps,et al.  IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. , 2006, Journal of the American Society of Nephrology : JASN.

[36]  E. Salido,et al.  Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  M. Barbagallo,et al.  Serum Ionized Magnesium Levels in Relation to Metabolic Syndrome in Type 2 Diabetic Patients , 2006, Journal of the American College of Nutrition.

[38]  L. Shaw,et al.  Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation , 2006, Therapeutic drug monitoring.

[39]  M. Bakkaloğlu,et al.  The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation. , 2006, Transplantation proceedings.

[40]  A. Hartmann,et al.  The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. , 2006, Kidney international.

[41]  T. Habuchi,et al.  Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplant Recipients Treated with Tacrolimus , 2005, Transplantation.

[42]  F. Bandrés,et al.  Association of the genetic polymorphisms of the renin-angiotensin system with kidney graft long-term outcome: preliminary results. , 2005, Transplantation proceedings.

[43]  S. Puumala,et al.  New-Onset Diabetes after Kidney Transplantation: An Application of 2003 International Guidelines , 2005, Transplantation.

[44]  S. di Paolo,et al.  Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.

[45]  A. Webster,et al.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data , 2005, BMJ : British Medical Journal.

[46]  T. Larson,et al.  New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. , 2005, Kidney international.

[47]  M. Schnitzler,et al.  Guidelines for the treatment and management of new‐onset diabetes after transplantation 1 , 2005, Clinical transplantation.

[48]  E. Benedetti,et al.  Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. , 2005, Transplantation proceedings.

[49]  T. Egeland,et al.  Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation , 2004, Diabetologia.

[50]  H. Volk,et al.  Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. , 2004, Kidney international.

[51]  R. Balshaw,et al.  New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta‐Analysis , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[53]  M. Schnitzler Diabetes Mellitus After Kidney Transplantation in the United States , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[54]  L. Pączek,et al.  Posttransplantation diabetus mellitus under calcineurin inhibitor. , 2003, Transplantation proceedings.

[55]  L. Rostaing,et al.  Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. , 2003, Journal of the American Society of Nephrology : JASN.

[56]  M. Rosenkoetter International expert panel. , 2003, Nursing outlook.

[57]  C.,et al.  New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. , 2003, Transplantation.

[58]  M. Schnitzler,et al.  Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait‐Listed and Transplanted Renal Allograft Recipients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[59]  M. Rodríguez-Moran,et al.  Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. , 2003, Diabetes care.

[60]  M. Rodríguez-Moran,et al.  Low serum magnesium levels and metabolic syndrome , 2002, Acta Diabetologica.

[61]  K. Brayman,et al.  Neoral® rescue therapy in transplant patients with intolerance to tacrolimus , 2002, Clinical transplantation.

[62]  M. Arias,et al.  Apolipoprotein C‐III and E Polymorphisms and Cardiovascular Syndrome, Hyperlipidemia, and Insulin Resistance in Renal Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[63]  C. Mathieu,et al.  Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. , 2001, Transplantation.

[64]  B. Wolffenbuttel,et al.  Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. , 2001, Journal of the American Society of Nephrology : JASN.

[65]  Hyun Chul Lee,et al.  Identification of glucokinase mutation in subjects with post-renal transplantation diabetes mellitus. , 2000, Diabetes research and clinical practice.

[66]  N. Ozdemir,et al.  Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. , 2000, Transplantation proceedings.

[67]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[68]  T. Egeland,et al.  Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. , 1997, Transplantation.

[69]  N. Al-Akash Diabetes mellitus after kidney transplantation. , 1995, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[70]  T. Fujimura,et al.  TRANSCRIPTIONAL INHIBITION OF INSULIN BY FK506 AND POSSIBLE INVOLVEMENT OF FK506 BINDING PROTEIN‐12 IN PANCREATIC β-CELL , 1995, Transplantation.

[71]  J. Habener,et al.  Wnt signaling in pancreatic islets. , 2010, Advances in experimental medicine and biology.

[72]  B. Krüger,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2008, The New England journal of medicine.

[73]  J. Neilson,et al.  Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. , 2006, Nature.